NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

NEUROCRINE BIOSCIENCES INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026

$136.98+1.27 (+0.94%)

Close on Oct 19, 2026

Market cap: $14.27B
P/E (TTM): 20.1
Dividend yield: –

NEUROCRINE BIOSCIENCES INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	2,861	2,355	1,887	1,489	1,134	1,046	788	451	162	15	20	0	2.92	53	77	34	2.95
Cost of Revenue	52	34	40	23	14	10	–	4.89	1.25	0	0	–	–	–	–	–	–
Gross Profit	2,808	2,321	1,847	1,466	1,119	1,036	–	446	160	15	20	–	–	–	–	–	–
Research & Development	1,016	731	565	464	328	275	–	161	122	94	81	46	39	37	31	31	34
Selling, General & Admin	1,156	1,007	888	753	583	433	354	249	170	68	32	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	68	32	18	13	13	12	13	14
Advertising Expenses	227	191	160	150	140	65	41	21	–	–	–	–	–	–	–	–	–
Operating Expenses	–	–	–	–	1,031	883	716	414	293	162	114	64	53	52	43	47	57
Total Costs & Expenses	2,241	1,785	1,636	1,240	1,031	883	–	–	–	–	–	–	–	–	–	–	–
Operating Income	619	571	251	249	103	163	72	37	-131	-147	-94	-64	-50	1.45	34	-14	-54
Interest Expense	–	–	4.60	7.10	26	33	32	31	20	0	0	–	–	–	–	–	–
Interest & Investment Income	–	–	–	–	–	–	–	–	–	2.84	1.93	0.63	0.40	0.49	0.44	0.40	–
Other Non-Operating Income	86	-85	81	-35	-1.10	-56	-26	-15	-11	6.28	5.27	3.87	3.59	3.58	3.65	5.75	2.63
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.56
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.02	-0.19	-1.09
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	–	–	0.00	0.04	0.03	3.20	0.29	0.84
Pretax Income	705	486	332	214	101	107	47	22	-143	-141	–	–	–	–	–	–	–
Income Tax Expense	227	145	82	59	12	-301	9.50	0.70	0	0	0	0	0	0	0	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	21	-143	-141	–	–	–	–	–	–	–
Net Income	479	341	250	155	90	407	37	21	-143	-141	-89	-61	-46	5.03	38	-7.97	-51
Net Income to Common	479	341	250	155	90	407	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	4.81	3.40	2.56	1.61	0.95	4.38	0.40	0.23	-1.62	-1.63	-1.05	-0.81	-0.69	0.08	0.68	-0.15	-1.30
EPS (Diluted)(per share)	4.67	3.29	2.47	1.56	0.92	4.16	0.39	0.22	-1.62	-1.63	-1.05	-0.81	-0.69	0.08	0.67	-0.15	-1.30
Shares Outstanding (Basic, Weighted)(shares)	100	100	98	96	95	93	92	90	88	87	84	75	67	66	55	53	39
Shares Outstanding (Diluted, Weighted)(shares)	103	104	101	99	98	98	96	95	88	87	84	75	67	67	56	53	39
EBITDA	–	–	–	–	–	–	–	41	-129	-146	-93	-64	-49	2.11	35	-12	-50

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 98.0%
Operating margin: 23.6%
Net margin: 20.9%
Return on equity, FY2025: 16.4%

Financial strength

Current ratio: 1.87
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 38.0%

Valuation

P/E ratio: 20.1
Price to sales: 4.23
Price to book: 3.86
Dividend yield: –